Latest Bristol-Myers Squibb Stories
Parker Waichman LLP is Already Representing Dozens of Plaintiffs in Plavix Gastrointestinal and Cerebral Bleeding Side Effect Lawsuits New York, NY (PRWEB) April 13, 2012 Parker Waichman LLP, a national law firm representing people injured by defective drugs, is investigating lawsuit claims on behalf of people who allegedly suffered severe bleeding side effects as a result of Plavix, a blood thinner made by Bristol -Myers Squibb Company and Sanofi-Aventis U.S., L.L.C. Parker Waichman LLP...
The results, which highlight the use of a novel drug called ARI-4175, may eventually point to new approaches that can be used in treating other cancers When combined with other treatments, the drug cetuximab—which works by slowing or stopping the growth of cancer cells—has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients—specifically those who carry a mutated form of a gene...
Adding the drug cetuximab to a regimen of drugs used for the treatment of patients following surgery for stage III colon cancer did not result in improved disease-free survival, according to a study in the April 4 issue of JAMA. Patients who have surgery for removal of stage III colon cancer have a 50 percent chance of cure. Multiple trials have established the benefit of chemotherapy after surgery in reducing the recurrence risk. "Specifically, [the drugs] leucovorin, fluorouracil, and...
NEW YORK, April 4, 2012 /PRNewswire/ -- Carl C. Icahn today issued the following open letter to the board of directors of Amylin Pharmaceuticals, Inc.: CARL C. ICAHN767 Fifth Avenue, 47th FloorNew York, New York 10153 April 4, 2012 Amylin Pharmaceuticals, Inc.9360 Towne Centre DriveSan Diego, California 92121 Attention: Board of Directors Re: The reports of your rejection of a $3.5 billion offer from Bristol-Myers Squibb Ladies and Gentlemen: As one of Amylin's largest...
BATON ROUGE, La., April 3, 2012 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals presented results from in vitro studies demonstrating synergy of EP-100 in combination with paclitaxel for the potential treatment of luteinizing hormone releasing hormone (LHRH)-receptor positive and multi-drug resistant cancers, including ovarian cancer, at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. Results have supported the...
Fox Chase scientists suggest that the findings could also serve as a new target for treatment Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings will be reported at the AACR Annual Meeting 2012 on Sunday, April 1. The researchers found that patients whose tumors had higher levels of the protein...
CALGARY, April 2, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018). "This is an important milestone for this study," said Dr. Brad Thompson, President and CEO of Oncolytics. "A data analysis that will...
Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet, the world's leading general medical journal. The article Point-of-care genetic testing for personalization of antiplatelet treatment (RAPID GENE): a prospective, randomized, proof-of-concept trial, reports on the use of a simple cheek swab test, the Spartan RX CYP2C19,...
SEATTLE, March 27, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that the University of Washington's ("UW") School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO(TM) (paclitaxel poliglumex, PPX, CT-2103) and radiation therapy ("RT") to the combination of temozolomide ("TMZ") and RT for patients with...
HONG KONG, March 22, 2012 /PRNewswire-Asia/ -- An infant formula product produced by Abbott Laboratories (ABT.NYSE), failed to reach China national safety standards and tested worst among a selection of six infant formula powders sold on the Chinese market, according to a research report released by Hong Kong-based research house CER Research on Thursday. The release of the research report on Abbott's Similac Stage 1 milk powder product coincided with Chinese media reports Wednesday...
